Poly Medicure Limited · NSE:POLYMED
Poly Medicure — Investor Presentation (May 2024)
22 slides from Poly Medicure's investor presentation, May 17, 2024
Slide 1: Submission of Investor's Presentation cover letter
Poly Medicure lim;ted Regd Office 232 B. 3rd Floor, Okhla lndustnc'.ll Estate, ·j:» POLYMED Phase-Ill, New Delhi - 110 020 (INDIA) • T:+91- ll -33550700,47317000 E: info@polymed,cure com W: polymed1cure.com CIN· L 40300DL 1995PLC066923 Date: 17111 May 2024 Scrip Code: - 531768 S;rip Code:- POLYMED T
Slide 2: Investor's Presentation, May 2024
Investor’s Presentation Poly Medicure Ltd. May 2024
Slide 3: Forward Looking Statement
Forward Looking Statement This presentation has been prepared by Poly Medicure Limited (the “Company”) solely for your information and may not be distributed, reproduced, or redistributed or passed on directly or indirectly to any other person, whether within or outside your organization or firm, or
Slide 4: Polymed at a Glance
We are commanding a formidable presence in the medical devices space Polymed at a Glance 12 12 Manufacturing Plants Specialities Across 4 countries 125+ Countries 200+ Medical Devices 4000+ 400+ Sales Associates Employee Base 400+ 1.2 Billion+ Devices Manufacturing Capacity Patents Per year
Slide 5: Navigating Our Journey: Path of Milestones and Triumphs
Navigating Our Journey Polymed's Path of Milestones and Triumphs 1997 2004 2009 2014 2018 2020 2023 Faridabad China Plant New Plant Renal Care New Plant in 4 New Plants Commencement (Dialysis) IMT Faridabad ,Expansion in of Manufacturing Plant 2 -Poly Medicure Operations (Laiyang) Co. Ltd. SEZ Jaipu
Slide 6: Polymed spearheads innovation across diverse healthcare domains
Polymed spearheads innovation across diverse healthcare domains, advancing towards a healthier world Billion Lives touched Annually FLUID MANAGEMENT PROCEDURAL MEDICAL DEVICES & EQUIPMENTS
Slide 7: Comprehensive Integration: Care Across the Hospital Spectrum
Comprehensive Integration Our Solutions Enhance Care Across the Hospital Spectrum IPD ICU Blood Bank Emergency Dialysis Centre Operation Theatre Specialty Treatment Units Oncology, Cardiology, Pathology Lab Gaestrontology, Urology
Slide 8: Our Innovations Deliver Vital Care to Key Clinical Specialties
Our Innovations Deliver Vital Care to Key Clinical Specialties Cardiology Anaesthesia & Respiratory Care Transfusion System Oncology Vascular Access Infusion Therapy Gastroenterology Diagnostics Urology Dialysis & Renal Care Surgery & Wound Drainage Critical Care
Slide 9: Diving into Our Product Portfolio
Diving into Our Product Portfolio Vascular Access Mini Mid Peripherally Inserted Peripherally inserted Central Venous Safety Introducer Safety Winged IV Cannula Arterial Catheter Catheters Lines - OTN Central Catheter Venous Catheters Infusion Set Needle Infusion Therapy Extension Lines with Infusio
Slide 10: Cardiology, Surgery and Wound, and other product lines
Cardiology Diagnostic Catheter PTCA Balloon PTCA Balloon Hydrophilic Guidewire PTFE Coated Guidewire Dilation Catheter SC Dilation Catheter NC Guiding Catheter Surgery and Wound Closed Wound Drainage Suction Unit Closed Wound High Pressure Redon Under Water Thoracic Yankauer Yankauer Suction Unit wi
Slide 11: Industry vs Polymed
CAGR 15%* Industry Polymed CAGR 22% vs ▪ High Import Dependence ▪ Top exporter for disposable medical devices for 12 years in a ▪ Low investments in R&D row ▪ Limited manufacturing capabilities ▪ Strong emphasis on R&D ▪ Core stream ▪ Strong manufacturing capabilities with 12 Ultra-modern plants ▪ C
Slide 12: Value Creation Through Innovation and Streamlined Operational Models
Template Value Creation Through Innovation and Streamlined Operational Models GROW INNOVATE SCALE ▪ Foster sustainable ▪ Strategic ▪ Enhancing Manufacturing revenue expansion, Investments in Capacities to global scale. Striving for Margin High-Growth Areas ▪ Build flexibility into Growth Cardiology,
Slide 13: Polymed's Robust Manufacturing Footprint: 12 Plants
Polymed's Robust Manufacturing Footprint 12 State-of-the-Art Facilities across 3 continents 117,Faridabad, India IMT 1,Faridabad, India SEZ, Jaipur, India Laiyang-qingdao, 104-105,Faridabad Amaro, Italy Haridwar Plant, India IMT 2, Faridabad 115-116, Faridabad Jaipur Plant, India R & D Center, India
Slide 14: Mastering Manufacturing: Striving Towards Operational Excellence
Mastering Manufacturing Striving Towards Operational Excellence
Slide 15: Navigating the Path: Building Tomorrow's Healthcare Solutions
Navigating the Path Building Tomorrow’s Healthcare Solutions Started In 2028 1997 2002-09 2011-19 2020-24 2025 - 27 & beyond Commencement Product and facility New R&D Center, of Manufacturing expansion Acq of Plan 1 Health, Operation New Manufacturing › Launched › Prioritize the › Through a Plants d
Slide 16: Way Forward
Way Forward Research & Development ▪ Targeted R&D investments towards transformative therapeutic areas, aiming to pioneer breakthrough innovations Emphasizing Inorganic Growth ▪ Integration of AI and IoT technologies to enhance efficiency & precision Strategic Alliances to foster synergies and expan
Slide 17: Revenue Mix
Revenue Mix 2/3rd International 1/3rd India
Slide 18: Our Strength: Consistent all-round growth
Our Strength: Consistent all-round growth ₹ ₹ ₹ REVENUE (₹ Crs) EBIDTA (₹ Crs) PBT (₹ Crs) PAT (₹ Crs) 400.00 1600.00 500.00 344.27 300.00 1375.79 350.00 258.26 1400.00 419.50 300.00 250.00 1200.00 1115.23 400.00 237.49 179.28 923.06 303.50 250.00 200.00 1000.00 300.00 195.24 146.51 253.45 200.00 15
Slide 19: Ratios (in %)
Ratio’s (in %) Interest Service Debt Service Coverage 16 14.70 70 64.53 14 60 48.52 12 50 10 9.42 40 37.56 8 6.87 30 6 20 4 10 2 0 0 FY 2022 FY 2023 FY 2024 FY 2022 FY 2023 FY 2024 ROCE ROE 25.00 20 20.94 17.26 18 20.00 17.48 16 14.51 13.56 14.05 14 15.00 12 10 10.00 8 6 5.00 4 2 0.00 0 FY 2022 FY 2
Slide 20: Delivering on our commitment of Value Creation
Delivering on our commitment of Value Creation Market Capitalization (in INR Crs) Shareholder Category in % 31 Mar’23 31 Mar’24 18000.00 15251.78 Promoters 53.31 53.15 16000.00 14000.00 12000.00 Institutional Investors 19.89 19.60 10000.00 9105.74 9140.14 8000.00 6000.00 Private Corporate Bodies 15.
Slide 21: Shareholders Return
Consistent Success Consistent Positive Performance over the Past 6 Quarters Shareholders Maximizing Returns • ROCE at 20.94 % Return Driving Growth Driving Growth Market Beating Performance • The NET SALES (Q) Highest at Rs 360 crs The stock has delivered Investors Returns* (3 years) a return of 62.
Slide 22: Towards our Commitment to a Sustainable World
Towards our Commitment to a Sustainable World Power consumption per 6.14% HSD Saving 26 Pits for production unit remains steady 30 KL Rain Harvesting; despite a 6% rise in production by convert Steam Boilers with 90% of the wastewater is and the launch of two new plants PNG & minimize HT Line faults